Heamolytic activities, deoxyribonuclease production and in-vitro flouroquinolones susceptibility profile of aerobic gram positive cocci associated with acne vulgaris
Keywords:
Acne vulgaris, Fluoroquinolones, Deoxyribonuclease, Heamolysis, SusceptibilityReferences
Akinjogunla, O.J., Eghafona, N.O., 2011. Prevalence, Haemolytic Activities and Flouroquinolones Susceptibility
Profiles of Moraxella catarrhalis, Streptococcus pneumoniae and Haemophilus influenzae Associated with
Acute Otitis Media. Natu. Sci. 9(6), 85-92.
Akinjogunla, O.J., Enabulele, O.I., 2010. Virulence factors, plasmid profiling and curing analysis of multi-drug
resistant Staphylococcus aureus and Coagulase negative Staphylococcus spp. isolated from patients with
acute otitis media. J. Amer. Sci. 6 (11), 1022-1033.
Asima, B., Eswari, L., Akilesh, H., 2011. Prospective study to determine the effectiveness of clindamycin (allopathy),
Berberis aquifolium (Oregon grape- homeopathy) and Azadirachta indica (neem-ayurvedic) medications
against the microorganism causing acne vulgaris. Inter. J. Basic Med. Sci. 2(2), 78-83.
Bek-Thomson, M., 2008. “Acne is not Associated with yet Uncultured Bacteria”. J. Clin. Microbiol. 46 (10), 3355 –
Bettoli, V., Borghi, A., Rossi, R., 2006. Antibiotic resistance of Propionibacterium. Four years’ experience of a large
number of cases in Italy. Dermatol. 212(2), 206-207.
Bowe, W.P., A.C., Logan, 2011. "Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future?" Gut
Pathog. 3(1), 1.
Dreno, B., Poli, F., 2003. Epidemiology of acne. Dermatol. 206, 7-10.
Farrar, M., 2007. Genome Sequence and analysis of a Propionibacterium acne. J. Bacteriol. 189 (11), 416 –4167.
Ferdowsan, H.R., Levin, S., 2010. "Does diet really affect acne?". Skin Therapy Lett. 15 (3), 1–2, 5.
Finegold, S.M., Baron, F.A., 1986. Baily and Scott’s Diagnostic Microbiology. (8th edn). Saunders co. Philadelphia.
Gollnick, H.P., Krautheim, A., 2003. Topical treatment in acne: current status and future aspects. Dermatol. 206,
-36.
Hassanzadeh, P., Bahmani, M., Mehrabani, D., 2008. Bacterial resistance to antibiotics in Acne vulgaris: An in vitro
study. Indian J. Dermatol. 53, 122–124.
Hiramatsu, J., Kataoka, M., Nakata, Y., 2003. “Propionibacterium acne DNA detected in chroncho alveolar lavage
cells from patients with sarcoidosis.” J. Sarcoid. Vascu. Diffuse. Lung. Dis. 20 (3), 197 – 203.
Nelson, J.M., Chiller, T.M., Powers, J.H., Angulo, F.J., 2007. “Flouroquinolones resistant Campylobacter species and
the Withdrawal of fluoroquinolones from use in poultry: a public health success story.” Clini. Infec. Dis. 44 (7),
– 980.
Pietro, N., 2006. Expert Review of Dermatology. J. Dermatol. 1 (5), 643 – 654.
Pochi, P.E., 1990. The pathogenesis and treatment of acne. Ann. Rev. Med. 15, 187-98.
Prescott, L.M., Harley, J.P., Klein, D.A., 2008. Microbiology. (7th edn). McGraw- Hill companies, Inc, New York. Pp
Prescott, L.M., Harley, J.P., Klein, D.A., 2011. Microbiology. (8th edn). McGraw-Hill companies, Inc, New York.
Pp.993.
Ray, C., Ryan, K.J., Kenneth, R., 2004. Sherrish Medical Microbiology: An introduction to infectious Diseases
McGraw Hill. Pp. 237.
Ross, J.I., SNelling A.M., Eady, E.A., Core, J.H., Cunliffe, W.J., Leyden, J.J., 2001. Phenotypic and genotypic
characterization of antibiotic resistant Propionibacterium acne isolated from acne patients attending
dermatology Clinics in Europe, Japan, USA and Australia. 144, 225 – 227.
Shweta, K., Swarnlata, S., 2011. Tropical herbal therapies and alternative and complementary choice to combat
acne. Res. J. Med. Plant. 5(6),650-669.
Silverberg, N.B., Weinberg, J.M., 2011. Rosaceae and adult acne: a worldwide epidemic. Cutis. 68, 85.
Talaro, K.P., Talaro, A., 2002. Foundations in Microbiology. (4th edn). McGraw-Hill companies, Inc, New York. Pp
Webster, G.F., 1998. Acne and Rosaceae. Medical Clinic North America. 82, 1145 – 54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 O.J. Akinjogunla, O.I. Medo, E.P. Philip
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.